Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DYP 688

Next Previous
Drug Profile

DYP 688

Alternative Names: DYP-688

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action GNA11 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Uveal melanoma

Most Recent Events

  • 30 May 2025 Pharmacokinetics, efficacy and adverse events data from a phase-I/II clinical trials in Uveal melanoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 08 Sep 2024 Pharmacokinetics data from a phase I/II trial in Uveal melanoma presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
  • 04 Jul 2022 Phase-I/II clinical trials in Uveal melanoma (Metastatic disease, In children, In adolescents, In adults, In the elderly) in USA, France, Germany, Netherlands, Spain and Switzerland (IV) (NCT05415072);

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top